Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + rituximab followed by R-DHAOx, autologous stem cell transplant, and maintenance therapy for untreated mantle cell lymphoma
ACTRN12619000990123Phase 2Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2 trial of acalabrutinib and rituximab, sponsored by Australasian Leukaemia & Lymphoma Group. Started Sep 2020; status: active, not recruiting.
02
Drugs
acalabrutinibrituximab
Beyond the preview
Go deeper on ACTRN12619000990123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000990123.